Diabetes und Fettleber

Norbert Stefan; Michael Roden

doi:10.1055/a-1193-3913

Diabetologie und Stoffwechsel, Inhaltsverzeichnis

Diabetologie und Stoffwechsel 2020; 15(S 01): S156-S159
DOI: 10.1055/a-1193-3913

DDG-Praxisempfehlung

Diabetes und Fettleber

Authors

Norbert Stefan

¹Deutsches Zentrum für Diabetesforschung (DZD)

²Heisenberg-Professur und Lehrstuhl für klinisch-experimentelle Diabetologie, Abteilung für Innere Medizin IV, Bereiche Endokrinologie, Diabetologie und Nephrologie, Universitätsklinikum Tübingen

³Abteilung Pathophysiologie des Prädiabetes des Instituts für Diabetesforschung und Metabolische Erkrankungen (IDM) des Helmholtz Zentrums München an der Universität Tübingen
Michael Roden

¹Deutsches Zentrum für Diabetesforschung (DZD)

⁴Klinik für Endokrinologie und Diabetologie, Medizinische Fakultät der Heinrich-Heine-Universität und Universitätsklinikum Düsseldorf

⁵Institut für Klinische Diabetologie, Deutsches Diabetes Zentrum (DDZ), Leibniz-Zentrum für Diabetesforschung an der Heinrich-Heine-Universität Düsseldorf

Abstract

Volltext

Referenzen

Literatur
1 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
2 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019; 70: 531-544
3 Eigentler T, Lomberg D, Machann J. et al. Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. Ann Intern Med 2020; 172: 836-837
4 Estes C, Anstee QM, Arias-Loste MT. et al. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 2018; 69: 896-904
5 Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313-324
6 Zaharia OP, Strassburger K, Strom A. et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019; 7: 684-694
7 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14: 32-42
8 European Association for the Study of the Liver (EASL); European European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
9 Chalasani N, Younossi Z, Lavine JE. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357
10 Bril F, McPhaul MJ, Caulfield MP. et al. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 2019; 67: 303-311
11 Singh S, Allen AM, Wang Z. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-654.e1–9
12 Adams LA, Anstee QM, Tilg H. et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153